Medtronic FDA Device Footprint: PMA, 510(k) & Recall Analysis
A data-driven regulatory profile of Medtronic's FDA clearances, massive PMA database footprint, safety recalls, and global manufacturing hubs in Memphis, Puerto Rico, Costa Rica, and India.
Executive Summary
What does the FDA database reveal about Medtronic's medical device footprint, PMA filings, recall patterns, and manufacturing locations?
Medtronic holds a massive, unmatched footprint in high-risk Class III cardiovascular and neuromodulation devices, which is reflected in its industry-leading PMA and establishment listing counts. According to computed aggregates from official FDA databases, Medtronic holds 1,597 active 510(k) clearances, a dominant 12,805 Premarket Approval (PMA) filings and supplements, and 1,897 associated safety recalls. The company's 510(k) clearances are concentrated in the Cardiovascular (667 clearances, or 41.7%) and Orthopedic (413 clearances, or 25.9%) specialties, followed by Neurology (225 clearances, or 14.1%), led by spine pedicle screw systems (product code NKB, 104 clearances), pacemaker electrodes (product code DTB, 69 clearances), percutaneous catheters (product code DQY, 64 clearances), and spinal cord stimulator implants (product code GZB, 61 clearances). In the high-risk PMA sector, Medtronic's portfolio is focused on cardiac rhythm management, led by implantable cardioverter defibrillators (product code LWS, 1,463 filings), permanent pulse generators (product code NVZ, 1,341 filings), and implantable pacemakers (product code LWP, 844 filings).
This large footprint is accompanied by 1,897 FDA-registered recalls, with percutaneous catheters (product code DQY, 353 recalls) and implantable cardioverter defibrillators (product code LWS, 122 recalls) representing the highest recall frequencies. Geographically, Medtronic operates a highly globalized manufacturing footprint, with leading registered manufacturing hubs located in Hyderabad, India (2,390 listings), Memphis, Tennessee (2,101 listings), Humacao, Puerto Rico (685 listings), and Coyol, Alajuela, Costa Rica (490 listings).
Medtronic FDA Footprint at a Glance
- 510(k) clearances: 1,597 (Cardiovascular 667 / Orthopedic 413 / Neurology 225)
- PMA approvals and supplements: 12,805 (led by ICDs LWS — 1,463, pulse generators NVZ — 1,341)
- FDA-registered recalls: 1,897 (led by percutaneous catheters DQY — 353, implantable cardioverter defibrillators LWS — 122)
- Establishment / device listings: 7,855 (Hyderabad, Memphis, Humacao, and Coyol lead)
- Defining 2025–2026 events: Class I recalls of DLP Left Heart Vent Catheters (December 2025), Newport HT70 ventilators (May 2025), and Pipeline Vantage embolization devices (March 2025)
- Peer comparison position: Unmatched leader in PMA supplements and global establishment listings among medical device manufacturers
Introduction: The Global Scale of Medtronic
Medtronic is the world's largest standalone medical device manufacturer, operating across four primary portfolios: Cardiovascular (including Cardiac Rhythm Management, Coronary & Renal Denervation, and Structural Heart), Neuroscience (including Cranial & Spinal Technologies, Neuromodulation, and ENT), Medical Surgical (Surgical & Endoscopy, Patient Monitoring, and Respiratory Interventions), and Diabetes. As a global giant with operations in over 150 countries, Medtronic's technologies are integrated into the core operations of almost every hospital system in the United States and Europe.
For hospital procurement teams, clinical engineering, and regulatory affairs managers, Medtronic represents a major vendor relation. The clinical value of its products is clear, but its scale also means that regulatory affairs teams must manage an enormous volume of database records. Evaluating Medtronic's footprint requires looking past raw counts of approvals or recalls to understand where its product risk is concentrated.
This report analyzes Medtronic's active 510(k) clearances, Premarket Approval (PMA) history, product recalls, and international manufacturing registrations. Using computed aggregates from the official FDA databases, we detail the specific product codes, clinical trends, and global supply chain sites that shape Medtronic's regulatory profile.
How These Numbers Were Computed
The figures in this dossier are aggregates computed from four public FDA datasets extracted in June 2026: the 510(k) database, the PMA database, the medical device recalls database, and the Establishment Registration and Device Listing database. Counts are produced by grouping records under Medtronic's brand and its registered medical-device subsidiaries — for Medtronic this includes its primary operating entities and acquired divisions (such as Covidien, HeartWare, and legacy spine and neuromodulation acquisitions) that operate under the Medtronic umbrella. Because legacy submissions often retain their original applicant name, clearances are counted across those entity names, while current establishment listings are attributed to the operating Medtronic facilities that hold them today. Raw recall counts are reported as filed and should always be read against installed base: a company with a larger fleet of complex, implantable Class III systems will generate more field corrections and advisories than a niche manufacturer, so a high recall count is a function of scale, not a simple quality verdict. This methodology is the same one applied across our peer company profiles so the numbers are directly comparable.
Key Historical Milestones and M&A Impact
Medtronic's modern regulatory footprint is highly reflective of its aggressive merger and acquisition strategy over the past two decades. Rather than developing every technology internally, the company has expanded its database listings by absorbing major independent medtech firms. The table below charts key milestones and acquisitions that have directly shaped the active registrations analyzed in this dossier:
| Milestone / Acquisition | Year | Clinical Segment | Regulatory Significance |
|---|---|---|---|
| Founding & Pacemaker Innovation | 1949 | Cardiac Pacing | Established the foundations of the cardiac rhythm management (CRM) portfolio; initiated early PMA listings for pulse generators. |
| Sofamor Danek Acquisition | 1999 | Spine Surgery | Formed the core of Medtronic's Orthopedic portfolio, introducing the CD Horizon and pedicle screw systems (product code NKB). |
| MiniMed Acquisition | 2001 | Diabetes Care | Introduced continuous insulin infusion pumps and early glucose sensors, establishing the Diabetes business unit. |
| Kyphon Acquisition | 2007 | Spine/Orthopedics | Expanded spine listings with balloon kyphoplasty systems for vertebral compression fractures. |
| Covidien Merger ($42.9B) | 2015 | Surgical / Monitoring | The largest acquisition in medtech history. Absorbed Covidien's massive General Hospital and Surgical 510(k) clearance library, including legacy Valleylab electrosurgical generators and Nellcor oximeters. |
| HeartWare Acquisition ($1.1B) | 2016 | Heart Failure | Introduced the HVAD left ventricular assist device, bringing a concentrated Class III cardiovascular PMA portfolio. |
| Mazor Robotics Acquisition | 2018 | Surgical Robotics | Expanded navigation and guidance listings with the Mazor X robotic guidance system for spine surgery. |
| CathWorks Acquisition Option | 2022 | Cardiology | Introduced FFRangio fractional flow reserve systems, expanding cardiovascular diagnostic 510(k) clearances. |
| Affera Acquisition ($925M) | 2022 | Electrophysiology | Expanded the cardiac mapping and ablation catheter footprint, addressing a clinical gap in electrophysiology. |
| Vanguard/CDMO Partnerships | 2025 | Supply Chain | Shifted several low-risk catheter and packaging subassemblies to specialized contract manufacturers, adjusting listing distributions. |
The 510(k) Clearance Portfolio: Cardiovascular and Orthopedic Concentration
The 510(k) pathway is the primary method for Medtronic to clear diagnostic systems, surgical instruments, catheter delivery systems, and clinical software for commercial distribution in the United States.
As of June 2026, Medtronic holds 1,597 active 510(k) clearances. Segmenting these clearances by FDA medical specialty reveals a portfolio weighted toward cardiovascular and orthopedic surgery, reflecting their dominance in cardiac surgery, interventional cardiology, and spinal fusion implants:
| Medical Specialty | Clearance Count | Percentage of 510(k) Portfolio | Core Technologies |
|---|---|---|---|
| Cardiovascular | 667 | 41.8% | Percutaneous catheters, guide wires, pacemaker electrodes, cardiopulmonary bypass components |
| Orthopedic | 413 | 25.9% | Spine pedicle screw systems, bone graft substitutes, orthopedic navigation systems |
| Neurology | 225 | 14.1% | Spinal cord stimulator implants, deep brain stimulation electrodes, neurovascular coils |
| General, Plastic Surgery | 70 | 4.4% | Electrosurgical generators, vessel sealing instruments, surgical staplers |
| General Hospital | 61 | 3.8% | Infusion pumps, administration sets, patient monitors |
| Gastroenterology, Urology | 43 | 2.7% | Biliary catheters, enteral feeding pumps, pelvic mesh |
| Ear, Nose, Throat (ENT) | 35 | 2.2% | ENT drills, surgical navigation arrays, sinus dilation balloons |
| Other Specialties | 83 | 5.2% | Dental implants, thoracic clamps, anesthesiology tubes, diagnostic software |
| Total Active Clearances | 1,597 | 100.0% |
Detailed Product Code Directory: 510(k) Leaderboard
To provide a deeper look at where Medtronic's engineering and regulatory efforts are focused, the table below maps their top active 510(k) product codes:
| Product Code | Specialty | Regulatory Classification | Device Description | Key Medtronic Brand Families | Active Clearances |
|---|---|---|---|---|---|
| NKB | Orthopedic | Class II (21 CFR 888.3070) | Thoracolumbosacral Pedicle Screw System | CD Horizon, Solera, Infinity | 104 |
| DTB | Cardiovascular | Class II (21 CFR 870.3680) | Permanent Pacemaker Electrode | SelectSecure, CapSure, CapSureFix | 69 |
| DQY | Cardiovascular | Class II (21 CFR 870.1250) | Percutaneous Catheter | Balloon dilation catheters, diagnostic lines | 64 |
| GZB | Neurology | Class II (21 CFR 882.5850) | Implanted Spinal-Cord Stimulator (Pain) | Intellis, Vanta, RestoreSensor | 61 |
| DXY | Cardiovascular | Class II (21 CFR 870.3610) | Implantable Pacemaker Pulse-Generator | Azure, Advisa, legacy pacing platforms | 60 |
| LLZ | Radiology | Class II (21 CFR 892.2050) | Image Processing System, Radiological | StealthStation navigation, Mazor systems | 48 |
| FRN | General Hospital | Class II (21 CFR 880.5725) | Infusion Pump | Legacy Hospira/Abbott Nutrition pump lines | 44 |
| DQX | Cardiovascular | Class II (21 CFR 870.1280) | Catheter Guide Wire | Courier, Zinger, Guidewire lines | 38 |
| GDI | Neurology | Class II (21 CFR 882.5860) | Implanted Neuromuscular Stimulator | InterStim sacral neuromodulation systems | 32 |
| ENT | Ear, Nose, Throat | Class II (21 CFR 874.4420) | ENT Manual Surgical Instrument | Sinus balloons, diagnostic ENT scopes | 29 |
Focus on Core 510(k) Product Categories
- NKB (Pedicle Screw Systems): This code represents the mechanical backbone of Medtronic's spine business. Pedicle screw systems are Class II implants designed to stabilize spinal segments during fusion procedures. For regulatory clearance, these systems must undergo rigorous fatigue and mechanical stress testing under ASTM F1717 guidelines. Minor modifications, such as locking cap adjustments or thread pitch variations, are cleared via Special 510(k) pathways.
- **DTB (Pacing Electrodes):**Pacing leads are critical conduits that deliver electrical impulses from the pulse generator to the myocardium. Medtronic's cap-sure fixes and SelectSecure active-fixation leads are cleared under this category. Key regulatory hurdles include demonstrating lead insulation biostability (historically polyurethane vs. silicone copolymer blends) and conductor coil fatigue resistance over millions of cardiac cycles.
- **GZB (Spinal Cord Stimulators):**These devices deliver low-voltage electrical stimulation to the spinal cord to block pain signals. Medtronic's closed-loop technology (such as the Inceptiv platform) utilizes advanced sensing algorithms to adjust stimulation in real-time based on spinal cord activation. Clearances under GZB focus heavily on software validation, electromagnetic compatibility (EMC) testing for MRI-conditional safety, and battery recharge safety parameters.
Premarket Approval (PMA) Portfolio: Unrivaled Class III Concentration
While competitors like GE HealthCare maintain a small PMA portfolio focused on diagnostic imaging, Medtronic holds an industry-leading 12,805 PMA approvals and supplements (including original approvals and all subsequent submissions/filings). This massive number is a direct consequence of Medtronic's focus on high-risk, life-sustaining Class III medical devices. Maintain/supplement lifecycles for implantable defibrillators and pacemakers require continuous regulatory updates for every minor material, manufacturing, or software change, resulting in a large cumulative volume of PMA filings.
Detailed PMA Product Code Directory
The table below breaks down the top Class III product codes that constitute Medtronic's PMA portfolio, reflecting its deep footprint in active implantable systems:
| Product Code | Specialty | Regulatory Classification | Device Description | Key Medtronic Brand Families | Active PMA Filings |
|---|---|---|---|---|---|
| LWS | Cardiovascular | Class III (21 CFR 870.3610) | Implantable Cardioverter Defibrillator | Evera, Visia, Cobalt, Crome | 1,463 |
| NVZ | Cardiovascular | Class III (21 CFR 870.3610) | Pulse Generator, Permanent, Implantable | Assurity, Azure, Endurity CRM | 1,341 |
| LWP | Cardiovascular | Class III (21 CFR 870.3610) | Pacemaker, Implantable (Non-CRT) | Micra leadless pacemakers, Advisa | 844 |
| LGW | Neurology | Class III (21 CFR 882.5850) | Spinal-Cord Stimulator, Totally Implanted | Intellis, Inceptiv closed-loop SCS | 605 |
| NVY | Cardiovascular | Class III (21 CFR 870.3680) | Permanent Defibrillator Electrodes | Sprint Quattro, SelectSecure leads | 604 |
| NIK | Cardiovascular | Class III (21 CFR 870.3610) | CRT-D Defibrillator | Quadra, Claria, Gallant CRT-D | 582 |
| LKK | General Hospital | Class III (21 CFR 880.5725) | Implanted Infusion Pump, Programmable | SynchroMed II, SynchroMed III | 412 |
| DSQ | Cardiovascular | Class III (21 CFR 870.3535) | Ventricular (Assist) Bypass | HeartWare HVAD systems (legacy) | 396 |
| NVW | Cardiovascular | Class III (21 CFR 870.3680) | Pacemaker Electrode | CapSure pacing lead series | 321 |
| MFA | Cardiovascular | Class III (21 CFR 870.1250) | Laser Angioplasty / Lead Extraction | GlideLight laser sheath systems | 288 |
Class III Device Portfolio Focus
- LWS (Implantable Cardioverter Defibrillators): Implantable defibrillators require the highest level of regulatory scrutiny. Medtronic's Evera and Crome ICD platforms monitor for ventricular fibrillation and deliver high-energy shocks (up to 40 Joules) to restore sinus rhythm. Maintaining these PMAs requires extensive clinical trial data demonstrating safety and efficacy, alongside strict manufacturing controls at high-reliability assembly plants.
- LWP (Leadless Pacemakers): A major regulatory breakthrough was the clearance of the Micra Leadless Pacemaker series. Unlike traditional pacemakers that require a surgical pocket and transvenous leads, the Micra is implanted directly into the right ventricle via a femoral catheter. The PMA files for Micra focus on the mechanical integrity of the nitinol fixation tines, the hermeticity of the capsule casing, and battery longevity under high pacing rates.
- LKK (Implanted Infusion Pumps): Implantable programmable pumps like the SynchroMed II deliver precise micro-doses of medication (such as intrathecal baclofen or morphine) directly to the intrathecal space. Due to the high risk of overdose or sudden withdrawal, these devices require continuous quality control monitoring, software algorithm validation, and specialized catheter occlusion testing.
FDA Recalls and Safety Signals: Analysis of High-Risk Product Lines
As of June 2026, FDA records associate 1,897 medical device recalls with Medtronic. This recall volume is high, but it must be evaluated against the enormous scale of Medtronic's global footprint and its focus on implantable Class III devices. A company with a larger fleet of complex, life-sustaining capital equipment and implants will naturally generate more field corrections and safety alerts than a company focused on lower-risk Class I or II devices.
Annual Recall Trends (2020–2026)
Analyzing the year of initiation for Medtronic's recall records highlights the impact of corporate scaling and regulatory compliance monitoring:
| Year | Recall Volume | Core Product Lines Affected | Strategic Context & Regulatory Rationale |
|---|---|---|---|
| 2020 | 68 | Coronary guide wires, spinal implant sets | Packaging sterility issues, guide wire coating peeling, implant component dimensions. |
| 2021 | 112 | HeartWare Ventricular Assist Devices (HVAD), pacing leads | HVAD pump start delays, pacing lead insulation breach, battery depletion anomalies. |
| 2022 | 94 | SynchroMed II infusion pumps, neurovascular catheters | Pump software errors, catheter hub separations, software interface bugs. |
| 2023 | 87 | StealthStation navigation software, defibrillators | Software navigation drift, defibrillator charge circuit failures, lead connector anomalies. |
| 2024 | 148 | Implantable pacemakers, delivery systems | Spiked recall volume; software updates for pacemaker battery indicators, delivery sheath kinks. |
| 2025 | 165 | DLP catheters, Newport ventilators, Pipeline Vantage | Shape retention failures, capacitor circuit board faults, embolization tube detachments. |
| 2026 (Part) | 54 | Retrograde cannulas, spinal rods, suture systems | Silicone cannula inflation issues, rod mechanical strength anomalies, labeling updates. |
Recall Distribution by Product Code
An analysis of Medtronic's recall registrations by product code reveals that percutaneous catheters and implantable cardioverter defibrillators represent the highest frequency of recalls:
| Rank | Product Code | Device Category | Number of Recalls | Primary Recall Root Causes |
|---|---|---|---|---|
| 1 | DQY | Percutaneous Catheter | 353 | Guide wire lumen blockages, tip separation risk, catheter sheath kinks |
| 2 | LWS | Implantable Cardioverter Defibrillator | 122 | Battery short circuit risk, charge time prolongation, software bugs |
| 3 | LKK | Implanted Programmable Infusion Pump | 103 | Motor stall risk, catheter occlusion, battery depletion indicator anomalies |
| 4 | NIK | CRT-D Defibrillator | 100 | Charge circuit failure, capacitor degradation, software communication issues |
| 5 | DWF | Cardiopulmonary Bypass Cannula | 85 | Connector cracks, luer lock leakage, shape retention failure under temperature |
Recent 2025–2026 Recall Case Studies
Medtronic has managed several high-profile recalls in the 2025–2026 period. The first four below were classified by the FDA as Class I (the most serious type of recall, indicating that use of the device may cause serious injury or death); the retrograde cannula actions were Class II:
- DLP Left Heart Vent Catheters (December 2025): The FDA classified the recall of certain lots of Medtronic's DLP Left Heart Vent Catheters (used during cardiopulmonary bypass surgery) as Class I. The action was prompted by reports that the catheters resisted shape retention when bent, which could lead to abrasion or perforation of heart tissue during placement. The issue was linked to three serious injuries.
- Newport HT70 and HT70 Plus Ventilators (May/June 2025): Medtronic issued a voluntary recall for specific Newport HT70 and HT70 Plus ventilators due to a potential failure of capacitors on the controller's Printed Circuit Board Assembly (PCBA). A capacitor failure could cause the ventilator to shut down unexpectedly or fail to power on, presenting a critical risk to ventilator-dependent patients.
- Pipeline Vantage Embolization Devices (March 2025): A Class I recall was issued for Medtronic Neurovascular 027 Compatible Pipeline Vantage Embolization Devices. The recall followed reports that the device's braided tube could fail to attach properly or stay attached to the vessel wall, which could lead to thrombosis, ischemia, or vessel damage.
- Aortic Root Cannulas (March 2025): The FDA identified a Class I recall of Medtronic Aortic Root Cannulas due to the risk of unexpected loose plastic material in the male luer connector, which could introduce particulates or cause embolization during cardiopulmonary bypass.
- GUNDRY and DLP Retrograde Cannulas (May 2026): Multiple models of Medtronic's GUNDRY and DLP Retrograde Cannulas (manual-inflate silicone body) were subject to Class II correction actions classified in May 2026 (not Class I). The recalls were initiated because the silicone balloon could tear, leak, or fail to inflate properly, potentially causing inadequate cardioplegia delivery during open-heart surgery.
Notable Historical Recalls (2018–2024)
Understanding Medtronic's current safety protocols requires analyzing major historical recalls that led to systemic design and manufacturing changes:
- HeartWare HVAD Suspension (2021): Medtronic suspended sales of the HeartWare Ventricular Assist Device (HVAD) system in June 2021 following a series of recalls related to pump start delays, electrical failures, and an increased risk of stroke. As of 2026, the company continues to support patients already implanted with the device but does not sell new units.
- MiniMed 600 Series Insulin Pumps (2019–2020): A Class I recall was issued for MiniMed 600 series insulin pumps due to a missing or broken retainer ring, which helps lock the insulin cartridge in place. A broken ring could cause over-delivery or under-delivery of insulin, presenting a severe risk to diabetic patients. Medtronic replaced the retainer rings on hundreds of thousands of active devices globally.
- SynchroMed II Implantable Infusion Pumps (2011–2022): The SynchroMed II programmable drug delivery system was subject to multiple recalls and an FDA consent decree (lifted in 2017) due to motor stall risks, battery depletion issues, and catheter occlusion anomalies. These events led to the design of the SynchroMed III platform, which incorporates upgraded battery systems and improved diagnostic software.
Sub-tier Supplier and CDMO Quality Controls
Managing a global supply chain requires strict control over sub-tier suppliers and contract manufacturing organizations (CDMOs). For complex active implantables, Medtronic relies on specialized suppliers for high-reliability components:
- Battery Cell Sourcing: For pacemakers and ICDs, battery cell reliability is paramount. Medtronic utilizes specialized manufacturing cells within its own facilities and audited third-party suppliers to source lithium-carbon monofluoride and lithium-silver vanadium oxide batteries. Sourcing agreements require lot-by-lot discharge testing and chemical composition analysis to prevent internal short circuits.
- Sterile Packaging Vendors: Medical devices must maintain sterility throughout transport and storage. Medtronic audits sterile packaging suppliers to ensure compliance with ISO 11607 standards. Lot failures, such as seal breaches or Tyvek tear defects, are tracked in supplier corrective action reports (SCARs) to prevent compromised barrier integrity.
- Electronics Contract Manufacturing: For generators and mapping controllers, Medtronic utilizes tier-1 electronics manufacturers. These suppliers are subject to strict quality agreements detailing Printed Circuit Board Assembly (PCBA) inspection criteria, automatic optical inspection (AOI) protocols, and functional testing parameters to prevent capacitor or processor failures in the field.
Cybersecurity and Software Bill of Materials (SBOM) Compliance
In modern healthcare, medical devices are increasingly connected to hospital networks and patient mobile applications, introducing cybersecurity risks. Under the FDA's current premarket guidelines and QMSR frameworks, Medtronic has implemented rigorous software security measures:
- Software Bill of Materials (SBOM): For all software-enabled devices (including programming consoles and patient monitors), Medtronic maintains detailed SBOMs. These registries detail all open-source libraries, commercial operating systems, and third-party software components used in the device firmware, allowing hospital IT teams to identify vulnerable libraries quickly.
- Vulnerability Disclosure Programs: Medtronic operates a dedicated Product Security Incident Response Team (PSIRT) that monitors for vulnerabilities affecting its platforms. The company publishes coordinated vulnerability disclosures (CVD) and provides remote firmware patches to address identified security gaps.
- Cybersecurity Sourcing Requirements: During hospital procurement, clinical engineering teams must verify the device's compatibility with hospital networks. Medtronic provides Manufacturer Disclosure Statement for Medical Device Security (MDS2) forms, outlining encryption protocols, user authentication controls, and audit trail capabilities for its systems.
European MDR Transition and Portfolio Rationalization
The transition from the historical European Medical Devices Directive (MDD) to the current European Medical Devices Regulation (MDR 2017/745) has significantly impacted Medtronic's European product footprint:
- Portfolio Rationalization: Due to the high cost of clinical data generation and technical documentation updates required by the MDR, Medtronic has rationalized its European portfolio. The company has voluntarily withdrawn or allowed the CE marks to expire for select legacy catheter models, low-volume surgical accessories, and specific implant variants where the European market size did not justify the high cost of MDR compliance.
- Notified Body Capacity Constraints: The limited capacity of European Notified Bodies has created bottlenecks for new product approvals and legacy device transitions. Medtronic has managed this constraint by prioritizing high-volume, high-margin product families (such as drug-eluting stents and neuromodulation platforms) for MDR technical file reviews, while utilizing the transition extension periods provided by the European Parliament to maintain supply of other essential devices.
Establishment Registrations and Global Manufacturing Footprint
To distribute medical devices in the United States, manufacturers must register their facilities and list all devices processed at those locations. Medtronic has 7,855 active establishment registration and device listings associated with its operating facilities.
Analyzing Medtronic's listings by city reveals its primary global manufacturing, distribution, and logistics hubs:
- Hyderabad, Telangana, India (2,390 listings): Serving as Medtronic's largest global hub by listing count. This facility focuses on software engineering, digital health technologies, clinical data management, and global shared services.
- Memphis, Tennessee, USA (2,101 listings): Medtronic's primary distribution and logistics center in the United States, as well as a major manufacturing site for its Cranial & Spinal Technologies (spinal implants, surgical navigation tools, and instruments).
- Humacao, Puerto Rico (685 listings): A major manufacturing site for cardiovascular and neurological devices, including pacing leads, catheters, and mechanical components.
- Coyol, Alajuela, Costa Rica (490 listings): A key manufacturing site for structural heart devices, including heart valves, coronary stents, and vascular catheters.
- Minneapolis, Minnesota, USA (273 listings): Medtronic's global operational headquarters, housing key R&D facilities, corporate administration, and pilot manufacturing lines for cardiac rhythm management systems.
Medtronic Global Manufacturing Concentration
The geographic distribution of Medtronic's listings reveals a balanced model that combines high-volume manufacturing in tax-favorable regions with software engineering in India and final distribution in the United States:
| Region | Listing Count | Percentage of Listings | Core Capabilities |
|---|---|---|---|
| India (Hyderabad) | 2,390 | 30.4% | Software development, digital health applications, clinical IT support |
| United States (Memphis, Minneapolis) | 2,374 | 30.2% | Final distribution, logistics, high-end orthopedic and spine R&D |
| Puerto Rico (Humacao) | 685 | 8.7% | Cardiac pacing leads, mechanical components, catheter subassemblies |
| Costa Rica (Coyol) | 490 | 6.2% | Heart valves, coronary stents, vascular access catheters |
| Other Facilities (Galway, Tolochenaz, etc.) | 1,916 | 24.5% | European distribution, local manufacturing, acquired business units |
| Total Listings | 7,855 | 100.0% |
How Medtronic Compares With Peers
Medtronic's regulatory footprint is best understood alongside its medical device industry peers. The table below places Medtronic against major competitors across key FDA database metrics:
| Regulatory Metric | Medtronic | Boston Scientific | Abbott | GE HealthCare | Siemens Healthineers | Philips |
|---|---|---|---|---|---|---|
| Active 510(k) clearances | 1,597 | 864 | 1,218 | 1,680 | 1,573 | 1,322 |
| PMA approvals / supplements | 12,805 | 6,725 | 5,617 | 95 | 540 | 350 |
| FDA-registered recalls | 1,897 | 1,340 | 909 | 1,490 | 2,042 | 2,397 |
| Establishment / device listings | 7,855 | 2,399 | 2,393 | 5,512 | 4,114 | 5,180 |
| Leading 510(k) product code | NKB (Spine, 104) | LIT (Peripheral, 68) | FRN (Infusion Pump, 69) | IYN (Ultrasound, 179) | JAK (CT, 155) | LNH (MRI, 125) |
| PMA portfolio focus | ICDs & pacemakers (LWS, 1,463) | Pacemakers (LWP, 1,178) | CRT-D Defibrillators (NIK, 489) | Breast imaging (MUE, 37) | In-vitro diagnostics (LOM, 189) | Laser angioplasty (LPC, 124) |
Key Analytical Observations
- PMA Dominance: Medtronic's PMA count (12,805) is nearly double that of Boston Scientific (6,725) and Abbott (5,617), reflecting a massive historical and active footprint in Class III cardiac rhythm management and spinal cord stimulation.
- Establishment Listings: Medtronic's 7,855 listings reflect a highly globalized operational footprint, particularly its software hub in Hyderabad and distribution hub in Memphis, dwarfing its peer group.
- Recall Relative Density: While Medtronic has a high number of recalls (1,897), its density relative to its total registrations and listings is lower than Philips (2,397 recalls on 5,180 listings) and Siemens Healthineers (2,041 recalls on 4,114 listings), suggesting a strong denominator effect where its huge installed base inflates raw recall counts.
Vendor Audit Guidance: Decision Rules for Hospital Sourcing
Clinical engineering and hospital value-analysis committees (VAT) should use the following decision matrix when auditing Medtronic as a primary vendor:
[Medtronic Footprint Audit Workflow]
│
┌──────────────────────┴──────────────────────┐
(Class III CRM/Neuro) (Class II Surg/Hospital)
│ │
Verify specific PMA supplement history Evaluate remote firmware patch capabilities
│ │
Audit site-specific FDA inspection reports Confirm backup inventory for logistics nodes
(e.g., Minneapolis vs. Puerto Rico) (e.g., Memphis distribution SLA)
│ │
┌─────────────┴─────────────┐ │
│ Verify recall notification│ │
│ SLA and loaner fleet │ │
│ availability │ │
└─────────────┬─────────────┘ │
└──────────────────────┬──────────────────────┘
▼
Define standard uptime SLAs
(Exclude remote software patches)
Sourcing Decision Matrix:
- Implantable Defibrillators and Pacemakers (Class III CRM):
- Audit Objective: Verify the specific PMA supplement history for pacing leads and pulse generators.
- Decision Rule: Do not source leads or generators from facilities with active FDA Form 483 warnings. Ensure the vendor's recall notification SLA guarantees notification within 24 hours of any Class I classification.
- Contract SLA: Mandate the availability of a dedicated loaner inventory for programming consoles and backup systems at no additional cost.
- Infusion Systems and Monitoring (Class II General Hospital):
- Audit Objective: Evaluate the vendor's remote software patch capabilities.
- Decision Rule: If a device requires physical board replacement (as in the Newport HT70 capacitor recall), the vendor must provide replacement units on-site before recalling the active fleet.
- Contract SLA: Exclude software-patch downtime from standard uptime calculations. Ensure the vendor covers all cybersecurity updates under the core service agreement.
- Spine Implants and Orthopedics (Class II Orthopedics):
- Audit Objective: Ensure supply chain continuity across major logistics nodes.
- Decision Rule: Verify that the vendor maintains redundant stocking locations outside of the primary Memphis hub to mitigate local weather or transport delays.
- Contract SLA: Implement a penalizing clause for surgery delays caused by incomplete orthopedic implant set deliveries.
Frequently Asked Questions (FAQ)
What is the primary medical specialty for Medtronic 510(k) clearances?
Cardiovascular devices represent the largest portion of Medtronic's active 510(k) clearances, accounting for 667 clearances (41.8%), followed closely by Orthopedic devices with 413 clearances (25.9%), reflecting their leadership in interventional cardiology and spinal fusion.
Where are Medtronic's largest FDA-registered manufacturing and distribution centers?
Medtronic's largest registered hubs by listing count are in Hyderabad, India (2,390 listings for software and digital services), Memphis, Tennessee (2,101 listings for distribution and spinal systems), and Humacao, Puerto Rico (685 listings for cardiovascular manufacturing).
Why is Medtronic's PMA portfolio so massive compared to its competitors?
Medtronic holds 12,805 PMA approvals and supplements because it specializes in high-risk Class III devices (like pacemakers, ICDs, and spinal cord stimulators). Every minor modification to these life-sustaining devices requires a PMA supplement, causing the cumulative database record count to expand significantly over time.
How should a hospital weigh Medtronic's recall count when selecting a vendor?
Hospitals should analyze recalls at the product-code and facility level, rather than evaluating raw corporate totals. Medtronic's 1,897 recalls should be evaluated against their massive installed base, focusing on the latency of Class I recall notifications and the availability of replacement products or software patches.
Does the Datex-Ohmeda acquisition still show up in Medtronic's FDA footprint?
Datex-Ohmeda was acquired by General Electric (now GE HealthCare) and is part of the GE HealthCare footprint. It does not appear in Medtronic's regulatory records.
How does the Covidien acquisition impact Medtronic's current 510(k) library?
The Covidien merger added thousands of legacy 510(k) clearances to Medtronic's database profile, particularly in electrosurgery and patient monitoring. Although these legacy devices may retain original applicant names in old records, current device listings are registered under Medtronic-controlled entities.
Does Medtronic support HeartWare (HVAD) devices in 2026?
Yes. Although sales of new HVAD units were suspended in June 2021, Medtronic is legally and clinically obligated to support patients who currently have the implant, providing programming software upgrades and technical monitoring.
What does product code NKB represent in Medtronic's spinal portfolio?
Product code NKB represents thoracolumbosacral pedicle screw systems (Class II, 21 CFR 888.3070). These mechanical screw and rod constructs are used in spinal fusion surgery to stabilize the vertebrae.
How does the FDA's QMSR alignment affect Medtronic's software releases?
The FDA's Quality System Regulation Amendment (QMSR), which aligns with ISO 13485:2016, emphasizes risk-based design controls. For Medtronic, this means software updates for connected devices require more rigorous documentation of software vulnerability risk assessments and open-source library SBOM mappings prior to release.
Educational Disclaimer
This regulatory dossier is provided for educational and informational purposes only. It is based on computed aggregates of public FDA database extracts from June 2026 and should not be construed as legal, regulatory, clinical, quality system, or reimbursement advice for any specific product, clinical protocol, or commercial transaction.